drugset / Trial / NCT04120636

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120636

Phase 1 Unknown 3 enrolled Targeted Therapy Technologies, LLC
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial will assess primarily the safety and secondarily the anti-inflammatory and anti-neovascular effect of Episcleral Celecoxib in patients suffering from macular edema and other inflammatory disorders of the retina, choroid and vitreous.

Timeline

Start
2021-03-05
Primary completion
2024-06-30
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified Other